Matches in Nanopublications for { ?s ?p "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- assertion description "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_assertion description "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_assertion description "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_provenance.
- NP1295233.RAJ4DKPPvcqZegwOJJBGewZL7ncJiCbUENr7uNS82l7dQ130_assertion description "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295233.RAJ4DKPPvcqZegwOJJBGewZL7ncJiCbUENr7uNS82l7dQ130_provenance.
- NP1295231.RA6z7U2JmwMVD8N-Y_0x-qhaQkcAVRFl_Jl90WxagCOLE130_assertion description "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295231.RA6z7U2JmwMVD8N-Y_0x-qhaQkcAVRFl_Jl90WxagCOLE130_provenance.